Justification of the change from 10% to 30% for the immunohistochemical HER2 scoring criterion in breast cancer

American Journal of Clinical Pathology

Volumn 132, Issue 1, 2009, Pages 74-79

  Liu, Yan Hui ^a   Xu, Fang Ping ^a   Rao, Jian Yu ^b   Zhuang, Heng Guo ^a   Luo, Xin Lan ^a   Li, Li ^a   Luo, Dong Lan ^a   Zhang, Fen ^a   Xu, Jie ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Fluorescence in situ hybridization; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCORING SYSTEM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL COUNT; DNA, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650447403     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPG3LCVKPNFJ6R     Document Type: Article

References (23)

1. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
2. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103-2111.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
5. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991-1998.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
8. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
9. Ridolfi RL, Jamehdor MR, Arber JM. HER2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
10. Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:179-184.
11. Diaz LK, Gupta R, Kidwai N, et al. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem. 2004;52:501-507.
12. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
13. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
14. Larsimont D, Di Leo A, Rouas G, et al. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Res. 2002;22:2485-2490.
15. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
16. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
17. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray-based assessment of outcome. J Clin Oncol. 2007;25:5418-5425.
18. Yaziji H, Goldstein LC, Barry TS, et al. HER2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977.
19. Lal P, Salazar PA, Hudis CA, et al. HER2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631-636.
20. Vera-Roman JM, Rubio-Martinez LA. Comparative assays for the HER2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004;128:627-633.
21. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15:94-102.
22. Hameed O, Chhieng DC, Adams AL. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? Am J Clin Pathol. 2007;128:825-829.
23. Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for Herceptin therapy. Am J Clin Pathol. 2008;129:907-911.